

プログラム

※本セミナーでとりあげる演題は、2016年6月2日～6月7日に開催される米国臨床腫瘍学会（ASCO）の年次総会の演題の中から重要なものをASCOのプログラム委員会が指定し、日本臨床腫瘍学会のBest of ASCO部会が選定したものです。但し、IDに * 印のある演題は日本臨床腫瘍学会のBest of ASCO部会が独自で選定したものです。

7月9日（土曜日）

as of 2016/07/01

Time	講師	司会	ASCO演題		
9:00	開場		ID	Abstract Title	Author
10:00-10:10	Welcome & Introduction 岡本 勇 九州大学				
10:10-10:40	Developmental Therapeutics		2503	Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.	Sara M. Tolaney, MD, MPH
	設楽 紘平 国立がん研究センター東病院	上野 秀樹 国立がん研究センター中央病院	3003	Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology.	Luis A. Diaz Jr., MD
10:40-10:50	Discussion: Q&A				
10:50-11:30	頭頸部がん		6000	Induction docetaxel platinum 5-FU (TPF) followed by cetuximab-radiotherapy (cetux-RT) versus concurrent chemo-radiotherapy (CT/RT) in patients with N2b/c-N3 non operated stage III-IV squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC 2007-02 phase III randomized trial.	Lionnel Geoffrois, MD
	横田 知哉 静岡県立静岡がんセンター	清田 尚臣 神戸大学医学部附属病院	6001*	Randomized phase III trial of induction chemotherapy (ICT) with docetaxel-cisplatin-5fluorouracil (DCF) followed by cisplatin-radiotherapy (CRT) or cetuximab-radiotherapy (CetRT) in patients (pts) with locally advanced unresectable head and neck cancer (LAUHNC).	Ricardo Hitt
			6007	Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial.	Li Zhang, MD
			6009	Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.	Robert L. Ferris, MD, PhD
11:30-11:45	Discussion: Q&A				
11:45-12:15	Patient and Survivor Care		10000	A URCC NCORP nationwide randomized controlled trial investigating the effect of exercise on chemotherapy-induced peripheral neuropathy in 314 cancer patients.	Ian Kleckner, PhD
	中島 貴子 聖マリアンナ医科大学	上田 弘樹 和歌山県立医科大学	10003	Randomized trial of early integrated palliative and oncology care.	Jennifer S. Temel
			10019	Placebo-controlled phase III study comparing dexamethasone on day1 to on day1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy.	Kunihiro Matsuzaki
12:15-12:25	Discussion: Q&A				
12:25-12:40	Break				
12:40-13:40	室 圭 愛知県がんセンター中央病院	兵頭 一之介 筑波大学	ランチョンセミナー 進行・再発大腸癌の最前線～2016Update～ / 中外製薬株式会社		
13:40-13:55	Break				
13:55-14:25	乳がん - Endocrine related therapy		LBA1	A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.	Paul E. Goss, MD, PhD
	佐治 重衡 福島県立医科大学	澤木 正孝 愛知県がんセンター中央病院	512	Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA).	Nicholas C. Turner, MD
			507	PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).	Richard S. Finn, MD
14:25-14:35	Discussion: Q&A				
14:35-15:05	乳がん - Chemo-／Antibody-／Local-therapy		500	Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).	Sara A. Hurvitz
	原 文堅 国立病院機構四国がんセンター	陳 勁松 がん研究会有明病院	1000	Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer.	Joanne Lorraine Blum, M.D., Ph.D.
			1005	A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01).	Atila Soran, MD, MPH
15:05-15:15	Discussion: Q&A				
15:15-15:30	Coffee Break 15分				
15:30-16:00	消化器がん - Colorectal Cancer		3504	Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).	Alan P. Venook, MD
	谷口 浩也 愛知県がんセンター中央病院	廣中 秀一 千葉県がんセンター	3511	The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.	Jeanne Tie
			3508*	A randomized trial comparing mesorectal excision with or without lateral lymph node dissection for clinical stage II, III lower rectal cancer: Primary endpoint analysis of Japan Clinical Oncology Group study JCOG0212.	Shin Fujita, MD, PhD
16:00-16:10	Discussion: Q&A				
16:10-16:50	消化器がん - Noncolorectal Cancer		LBA4001	FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.	Salah-Eddin Al-Batran, MD
	坂井 大介 大阪大学	森実 千種 国立がん研究センター中央病院	4005	NETTER-1 Phase III: Efficacy and Safety Results in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate.	Jonathan R. Strosberg, MD
			4000	A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study.	Marcel Verheij, MD, PhD
			LBA4006	ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.	John P. Neoptolemos, MD, PhD
16:50-17:05	Discussion: Q&A				
17:05-17:20	Break 15分				
17:20-18:05	高橋 俊二 がん研究会有明病院	吉田 明 神奈川県予防医学協会中央診療所/ 横浜市立大学	イブニングセミナー 甲状腺髄様癌における新規分子標的治療薬バンデタニブについて / サノフィ株式会社		

7月10日（日曜日）

Time	講師		司会	ASCO演題		
7:30	開場			ID	Abstract Title	Author
8:00-8:45	西尾 和人 近畿大学		佐治 重衡 福島県立医科大学	モーニングセミナー 進行がん治療における微小環境とEMT〜エリブリンのメカニズムからASCO2016まで〜 / エーザイ株式会社		
8:45-9:00	Break 15分					
9:00-9:20	Central Nervous System Tumors			LBA2	A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).	James R. Perry, MD
	佐々木 治一郎 北里大学	小野澤 祐輔 静岡県立静岡がんセンター		2003*	JCOG0504: A phase III randomized trial of surgery with whole brain radiation therapy versus surgery with salvage stereotactic radiosurgery in patients with 1 to 4 brain metastases.	Takamasa Kayama, MD, PhD
9:20-9:30	Discussion: Q&A					
9:30-10:00	婦人科がん			5501	Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.	Jonathan A. Ledermann, MD, FRCP
	松本 光史 兵庫県立がんセンター	温泉川 真由 国立がん研究センター中央病院		5508	Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG Symptom Benefit Study (SBS).	Felicia Roncolato
			5507	Performance characteristics and stage distribution of invasive epithelial ovarian/tubal/peritoneal cancers in UKTOCS.	Usha Menon, MD	
10:00-10:10	Discussion: Q&A					
10:10-10:40	泌尿器がん - Prostate Cancer			5006	Cabazitaxel vs docetaxel in chemotherapy-naïve (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A 3-arm phase III study (FIRSTANA).	Oliver Sartor, MD
	松原 伸晃 国立がん研究センター東病院	田畑 健一 北里大学		5008	Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).	Johann de Bono
			5001	A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12.	Goran Ahlgren, Ph.D	
10:40-10:50	Discussion: Q&A					
10:50-11:10	泌尿器がん - Nonprostate Cancer			4506	Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).	Toni K. Choueiri, MD
	近藤 千紘 虎の門病院	勝俣 範之 日本医科大学武蔵小杉病院		4503	Limited versus extended pelvic lymphadenectomy in patients with bladder cancer undergoing radical cystectomy: Survival results from a prospective, randomized trial (LEA AUO AB 25/02).	Juergen E. Gschwend
11:10-11:20	Discussion: Q&A					
11:20-11:35	Break 15分					
11:35-12:35	山崎 健太郎 静岡県立静岡がんセンター		山口 研成 がん研究会有明病院	ランチョンセミナー 切除不能大腸癌における分子標的治療薬の位置付け / 日本イーライリリー株式会社		
12:35-12:50	Coffee Break 15分					
12:50-13:10	血液がん - Leukemia, Myelodysplasia and Transplantation			7000	Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.	Jeffrey E. Lancet, MD
	南 陽介 神戸大学医学部附属病院	池田 宇次 静岡県立静岡がんセンター		7001	Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTfreedom study.	Andreas Hochhaus, Prof. Dr. med.
13:10-13:20	Discussion: Q&A					
13:20-13:50	血液がん - Lymphoma and Plasma Cell disorders			7504	Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study.	Pieterella J. Lugtenburg, MD, PhD
	丸山 大 国立がん研究センター中央病院	石塚 賢治 鹿児島大学		LBA4	Phase III randomized controlled study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): Castor study.	Antonio Palumbo, MD
			8000	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM Trial).	Michele Cavo, MD	
13:50-14:00	Discussion: Q&A					
14:00-14:30	肺がん - Non-small Cell			9008	Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study.	Hiroshi Nokihara, MD, PhD
	軒原 浩 国立がん研究センター中央病院	笠原 寿郎 金沢大学附属病院		9012	A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): LURET study.	Takashi Seto
			3001	CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.	Matthew David Hellmann, MD	
14:30-14:40	Discussion: Q&A					
14:40-15:10	肺がん - Small Cell			LBA8505	Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).	Charles M. Rudin, MD, PhD
	三浦 理 新潟県立がんセンター新潟病院	村上 晴泰 静岡県立静岡がんセンター		8504	CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCRTT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).	Corinne Faivre-Finn, MD, PhD
			100	CheckMate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).	Scott Joseph Antonia	
15:10-15:20	Discussion: Q&A					
15:20-15:30	Closing Remarks 山本 信之 和歌山県立医科大学					